<nowiki>Ad5-nCoV; Ad5-nCoV; Ad5-nCOV; Convidecia; کانسینو; Ad5-nCoV; AD5-nCOV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; എഡി5-എൻകോവ്; Ad5-nCoV; Convidecia; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; AD5-nCOV; Convidecia; Ad5-nCoV; vacuna de CanSino Biologics contra la COVID-19; COVID-19ワクチンの一つ; vacina para o covid-19; Chinese adenovirus-based vaccine against COVID-19; COVID-19疫苗; chinees COVID-19 vaccin; Convidecia; vacuna de CanSino; vacuna CanSino; vacuna de CanSino Biologics; PakVak; Convidecia; CanSino Biologics COVID-19 vaccine candidate; Convidecia; CanSino vaccine; PakVak; 克威莎; 克威莎2019冠状病毒病疫苗; Ad5-nCoV; vakcína od CanSino Biologics; Convidecia</nowiki>
Ad5-nCoV Chinese adenovirus-based vaccine against COVID-19 |
| Upload media |
|
| Instance of | |
|---|
| Subclass of | |
|---|
| Manufacturer | |
|---|
| Developer | |
|---|
| Significant event | - phase I clinical trial (108, A Single-center,Open-label, Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old, after 2020, –2021)
|
|---|
|
 |
